Your browser doesn't support javascript.
loading
Four distinct clinical phenotypes of vasculitis affecting medium-sized arteries.
Shirai, T; Shirota, Y; Fujii, H; Ishii, T; Harigae, H.
Afiliación
  • Shirai T; a Department of Hematology and Rheumatology , Tohoku University Graduate School of Medicine , Sendai , Japan.
  • Shirota Y; a Department of Hematology and Rheumatology , Tohoku University Graduate School of Medicine , Sendai , Japan.
  • Fujii H; a Department of Hematology and Rheumatology , Tohoku University Graduate School of Medicine , Sendai , Japan.
  • Ishii T; a Department of Hematology and Rheumatology , Tohoku University Graduate School of Medicine , Sendai , Japan.
  • Harigae H; a Department of Hematology and Rheumatology , Tohoku University Graduate School of Medicine , Sendai , Japan.
Scand J Rheumatol ; 48(4): 308-314, 2019 Jul.
Article en En | MEDLINE | ID: mdl-30672367
Objective: Within the spectrum of polyarteritis nodosa (PAN), cutaneous PAN (cPAN) is further classified into mild cPAN and severe cPAN which presents with ulcers, necrosis, or neuritis. As distinguishing between severe cPAN and systemic PAN can be difficult, this study evaluated the clinical characteristics of patients with necrotizing arteritis of medium-sized arteries. Methods: Forty-one patients diagnosed with necrotizing arteritis of medium-sized arteries between 2008 and 2017 at our institution were enrolled in this study. Clinical background, laboratory findings, treatments, and rates of relapse and death were evaluated. Results: Thirty-six patients were classified as having cPAN (mild, 15; ulcer, nine; neuritis, eight; both, four), and five cases manifested systemic vasculitis. Clinical characteristics of mild cPAN included female predominance (84.6%) and younger age (median 31 years); those of systemic PAN included older age (median 71 years) and higher levels of inflammatory markers. Severe cPAN manifested with intermediate phenotypes. The median doses of prednisolone used to treat mild cPAN, severe cPAN, and systemic PAN were 20.0, 40.0, and 40.0 mg/day, respectively. Immunosuppressants were used in 20.0% of mild cPAN, 90.5% of severe cPAN, and 80.0% of systemic PAN patients. Although the mortality rates were indistinguishable, the relapse rates of severe cPAN (ulcer type) were significantly higher than those of other types (88.9%). Conclusion: The clinical characteristics of mild cPAN, severe cPAN (ulcer type), severe cPAN (neuritis type), and systemic PAN were distinct from each other. In particular, patients with severe cPAN (ulcer type) had higher relapse rates, indicating the importance of combination therapy.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Poliarteritis Nudosa / Arterias / Enfermedades Cutáneas Vasculares / Vasculitis Sistémica / Inmunosupresores / Inflamación Tipo de estudio: Diagnostic_studies Límite: Adult / Aged / Female / Humans / Male País/Región como asunto: Asia Idioma: En Revista: Scand J Rheumatol Año: 2019 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Poliarteritis Nudosa / Arterias / Enfermedades Cutáneas Vasculares / Vasculitis Sistémica / Inmunosupresores / Inflamación Tipo de estudio: Diagnostic_studies Límite: Adult / Aged / Female / Humans / Male País/Región como asunto: Asia Idioma: En Revista: Scand J Rheumatol Año: 2019 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Reino Unido